JP2009540988A - 創傷被覆材 - Google Patents
創傷被覆材 Download PDFInfo
- Publication number
- JP2009540988A JP2009540988A JP2009517155A JP2009517155A JP2009540988A JP 2009540988 A JP2009540988 A JP 2009540988A JP 2009517155 A JP2009517155 A JP 2009517155A JP 2009517155 A JP2009517155 A JP 2009517155A JP 2009540988 A JP2009540988 A JP 2009540988A
- Authority
- JP
- Japan
- Prior art keywords
- wound dressing
- wound
- dressing according
- filament
- absorbent layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 polyethylene terephthalate Polymers 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000002250 absorbent Substances 0.000 claims abstract description 17
- 230000002745 absorbent Effects 0.000 claims abstract description 17
- 229910052709 silver Inorganic materials 0.000 claims abstract description 16
- 239000004332 silver Substances 0.000 claims abstract description 16
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920000098 polyolefin Polymers 0.000 claims abstract description 8
- 239000005020 polyethylene terephthalate Substances 0.000 claims abstract description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 claims abstract description 6
- 229920002239 polyacrylonitrile Polymers 0.000 claims abstract description 5
- 206010052428 Wound Diseases 0.000 claims description 89
- 208000027418 Wounds and injury Diseases 0.000 claims description 89
- 238000010521 absorption reaction Methods 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
- 229920002674 hyaluronan Polymers 0.000 claims description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 22
- 239000007788 liquid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000002816 chronic venous insufficiency Diseases 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 201000002282 venous insufficiency Diseases 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010048629 Wound secretion Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229920006378 biaxially oriented polypropylene Polymers 0.000 description 2
- 239000011127 biaxially oriented polypropylene Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000005026 oriented polypropylene Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229920001179 medium density polyethylene Polymers 0.000 description 1
- 239000004701 medium-density polyethylene Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000004749 staple nonwoven Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Description
・非架橋ヒアルロン酸1〜5mg/ml;
・次のものを調整するための緩衝物質および塩
−5.5〜6.0のpH値および
−250〜350ミリオスモル/kgのオスモル濃度;
・水。
実施例1
ポリエチレンテレフタレートおよびポリエチレンを溶融し、かつ該ポリエチレンに銀ゼオライトを2.5質量%の量で添加する。2つのポリマーの同時押出しを行い、その際、ポリエチレンテレフタレートはコアを形成する。温度降下および伸張によって2.9デシテックスの繊度に調整する。
実施例2a:銀の遊離の測定
銀イオンの遊離をICP−OES分析(誘導結合プラズマ発光分光分析法)によって測定した。遊離速度は60.15μg/100cm2であった。
吸収挙動の測定をDIN EN 13726−1 −吸収量に従って行った;該試験法は、液体と接触した際の吸引能と水蒸気の輸送を考慮した上での創傷被覆材の吸引特性の評価を下す。77.55g/100cm2の吸収力があるとわかった。
横方向の吸水性の測定を、DIN EN13726−2 −水蒸気の透過速度に従って行った;該試験法は、透過性のシート状複合材料の水蒸気の輸送速度の評価を下す。11mm/24hと測定された。
測定をDIN EN 13726.3 −防水度に従って行った;該試験法は、500mmの水柱の静水圧に300sのあいだ耐えられる能力の評価を下す。この場合、容量の約70%を保持することができた。20mmHgの圧力を用いた試験の場合、18g/100cm2を保持することができた。
製品は約290g/m2の全体質量および2.5mmの厚さを有していた。長手方向の引張強さ(EN29073−03)は31n/50mmであり、かつEN29073−03に従う長手方向の伸びは9%であった。
バイオ発酵によって獲得されたメディカルグレード(medical grade)のヒアルロン酸ナトリウム塩を品質試験にかけた。該製品は、400〜600kDaの分子量を有していた。タンパク質の含有率は≦0.3質量%、塩化物の含有率は≦0.5質量%および鉄の含有率は≦80ppmであった。
観察的研究
4週間の管理された観察的研究を、慢性静脈不全症(CVI)を患う10人の患者で、本発明による創傷被覆材を用いて週毎に3〜4回ドレッシングを交換しながら実施した。治療は湿潤治療として行った。自己水素化が十分ではない場合はリンガー液で補った。全ての患者をドキュメンテーションシステムにより把握しかつ記録した。患者は特別には選択されていなかったが、彼らは潰瘍の治療に重点をおいて診療所を頻繁に訪れる普通の患者(クライアント)に該当していた。その際、創傷の評価、観察をFalanga T.I.M.Eと同じように行った。
本発明によるドレッシングは、慢性創傷の場合に60%を上回る創傷部分の退縮を4週間内に達成するのに適している。
Claims (20)
- 少なくとも第一のおよび第二のフィラメントを包含する機能性フリースからの吸収層を包含する創傷被覆材であって、
その際、第一のフィラメントは、ポリエチレンテレフタレートからのコアとポリオレフィンからのシェルを包含し、かつ該シェル内には銀ソースが組み込まれており、かつ
その際、第二のフィラメントは、ポリアクリロニトリルからのコアとポリアクリルからのシェルを包含し、
その際、吸収層は水を0.15〜1.20ml/cm2吸収することができる
少なくとも第一のおよび第二のフィラメントを包含する機能性フリースからの吸収層を包含する創傷被覆材。 - 創傷被覆材が少なくとも2つの層を包含し、かつ10〜25μmの開口内径を有する疎水性材料からの傷口付近の層を包含することを特徴とする、請求項1記載の創傷被覆材。
- 傷口付近の層が、ポリオレフィン、殊にポリエチレンから成ることを特徴とする、請求項2記載の創傷被覆材。
- 吸収層の2つのフィラメントが一緒にらせんを形成することを特徴とする、請求項1から3までのいずれか1項記載の創傷被覆材。
- 吸収層が、水との接触に際して72時間にわたって創傷被覆材100cm2当たり銀イオン10μg〜100μgを放出することを特徴とする、請求項1から4までのいずれか1項記載の創傷被覆材。
- 第一のフィラメントおよび第二のフィラメントが互いに無関係に5〜20μmの直径を有することを特徴とする、請求項1から5までのいずれか1項記載の創傷被覆材。
- 第一のフィラメントおよび第二のフィラメントが互いに無関係に0.5〜2μmの直径を有するコアを有することを特徴とする、請求項1から6までのいずれか1項記載の創傷被覆材。
- 創傷付近の層と吸収層とが接着剤で結合されていることを特徴とする、請求項2から7までのいずれか1項記載の創傷被覆材。
- 吸収容量の50〜70%が30秒で吸収されうることを特徴とする、請求項1から8までのいずれか1項記載の創傷被覆材。
- 20mmHgの圧縮圧力下で少なくとも容量の50%を保持する能力があることを特徴とする、請求項1から9までのいずれか1項記載の創傷被覆材。
- 横方向の吸水性が24時間で5〜15mmであることを特徴とする、請求項1から10までのいずれか1項記載の創傷被覆材。
- 繊維フィラメントがそのコンシステンシーを維持することを特徴とする、請求項1から11までのいずれか1項記載の創傷被覆材。
- 第一のおよび第二のフィラメントが1:3〜3:1の質量比にあることを特徴とする、請求項1から12までのいずれか1項記載の創傷被覆材。
- 創傷の治療のための、請求項1から13までのいずれか1項記載の創傷被覆材の使用。
- 慢性創傷の治療のための、請求項13記載の使用。
- 請求項1から13までのいずれか1項記載の創傷被覆材およびヒアルロン酸含有スプレー液を含有するキット。
- 圧迫性潰瘍(褥瘡)、動脈性潰瘍、静脈性潰瘍、神経性潰瘍、熱傷、殊にIIa/IIb度の熱傷、術後の創傷、放射線創傷(放射線腫瘍)、細菌が原因の創傷または化学的に引き起こされた創傷の治療のための、請求項13記載の使用。
- 湿潤電極としての、請求項1から13までのいずれか1項記載の創傷被覆材の使用。
- ウォッシンググローブとしての、請求項1から13までのいずれか1項記載の創傷被覆材の使用。
- ウォッシングベッドとしての、請求項1から13までのいずれか1項記載の創傷被覆材の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06116313.5 | 2006-06-29 | ||
| EP06116313 | 2006-06-29 | ||
| EP06116317.6 | 2006-06-29 | ||
| EP06116317 | 2006-06-29 | ||
| PCT/EP2007/056321 WO2008000720A2 (de) | 2006-06-29 | 2007-06-25 | Wundauflage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009540988A true JP2009540988A (ja) | 2009-11-26 |
| JP4988838B2 JP4988838B2 (ja) | 2012-08-01 |
Family
ID=38728714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009517155A Expired - Fee Related JP4988838B2 (ja) | 2006-06-29 | 2007-06-25 | 創傷被覆材 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8350117B2 (ja) |
| EP (1) | EP2032179B1 (ja) |
| JP (1) | JP4988838B2 (ja) |
| AT (1) | ATE526998T1 (ja) |
| BR (1) | BRPI0713430A2 (ja) |
| CA (1) | CA2654916C (ja) |
| CY (1) | CY1112290T1 (ja) |
| DK (1) | DK2032179T3 (ja) |
| ES (1) | ES2374508T3 (ja) |
| PL (1) | PL2032179T3 (ja) |
| PT (1) | PT2032179E (ja) |
| SI (1) | SI2032179T1 (ja) |
| WO (1) | WO2008000720A2 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8350117B2 (en) | 2006-06-29 | 2013-01-08 | Biocell Gesellschaft Fuer Biotechnology Mbh | Wound cover |
| JP2016540593A (ja) * | 2013-12-20 | 2016-12-28 | エイチシーピー ヘルスケア アジア ピーティーイー.リミテッド | 空洞創傷を充填するための複合材料 |
| CN113682244A (zh) * | 2020-05-18 | 2021-11-23 | 日本宝翎株式会社 | 成型用基材 |
| JP2021181671A (ja) * | 2020-05-18 | 2021-11-25 | 日本バイリーン株式会社 | 成形用基材 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2547677T3 (es) | 2011-05-26 | 2015-10-08 | Biocell Gesellschaft Für Biotechnologie Mbh | Apósito funcionalizado |
| FR3085105B1 (fr) | 2018-08-22 | 2021-02-12 | Commissariat Energie Atomique | Nouvel agent antimicrobien a base de materiau polymerique particulaire poreux dope |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5721549A (en) * | 1980-07-09 | 1982-02-04 | Japan Exlan Co Ltd | Water absorbable nonwoven fiber product |
| JPH0754208A (ja) * | 1993-08-13 | 1995-02-28 | Teijin Ltd | 芯鞘型複合バインダー繊維 |
| JPH11200209A (ja) * | 1997-12-26 | 1999-07-27 | Toyobo Co Ltd | 衛生材料用成形吸収体 |
| WO2005000372A1 (ja) * | 2003-06-26 | 2005-01-06 | Zuiko Corporation | 創傷被覆材および創傷被覆材キット |
| JP2006169173A (ja) * | 2004-12-16 | 2006-06-29 | Toyobo Co Ltd | シート状パック材の使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3900198A1 (de) | 1989-01-05 | 1990-07-12 | Merck Patent Gmbh | Topisch anwendbare pharmazeutische zubereitung |
| US5550112A (en) | 1992-12-30 | 1996-08-27 | Patent Biopharmaceutics, Inc. | Hyaluronic acid-urea pharmaceutical compositions and uses |
| US5604200A (en) | 1994-05-02 | 1997-02-18 | Taylor-Mccord; Darlene | Wound therapeutic mixture containing medical grade hyaluronic acid and tissue culture grade plasma-fibronectin in a delivery system that creates a moist environment which simulates in utero healing |
| US6333093B1 (en) * | 1997-03-17 | 2001-12-25 | Westaim Biomedical Corp. | Anti-microbial coatings having indicator properties and wound dressings |
| GB0015682D0 (en) | 2000-06-28 | 2000-08-16 | Bristol Myers Squibb Co | Sprayable wound care composition |
| DE10108083B4 (de) | 2001-02-20 | 2004-02-19 | Lohmann & Rauscher Gmbh & Co. Kg | Wundauflage |
| US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
| US7592277B2 (en) * | 2005-05-17 | 2009-09-22 | Research Triangle Institute | Nanofiber mats and production methods thereof |
| US7323184B2 (en) * | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
| US8350117B2 (en) | 2006-06-29 | 2013-01-08 | Biocell Gesellschaft Fuer Biotechnology Mbh | Wound cover |
-
2007
- 2007-06-25 US US12/306,590 patent/US8350117B2/en not_active Expired - Fee Related
- 2007-06-25 AT AT07765600T patent/ATE526998T1/de active
- 2007-06-25 PL PL07765600T patent/PL2032179T3/pl unknown
- 2007-06-25 JP JP2009517155A patent/JP4988838B2/ja not_active Expired - Fee Related
- 2007-06-25 DK DK07765600.7T patent/DK2032179T3/da active
- 2007-06-25 CA CA2654916A patent/CA2654916C/en not_active Expired - Fee Related
- 2007-06-25 BR BRPI0713430-4A patent/BRPI0713430A2/pt not_active IP Right Cessation
- 2007-06-25 SI SI200730803T patent/SI2032179T1/sl unknown
- 2007-06-25 WO PCT/EP2007/056321 patent/WO2008000720A2/de not_active Ceased
- 2007-06-25 PT PT07765600T patent/PT2032179E/pt unknown
- 2007-06-25 EP EP07765600A patent/EP2032179B1/de not_active Not-in-force
- 2007-06-25 ES ES07765600T patent/ES2374508T3/es active Active
-
2011
- 2011-12-12 CY CY20111101229T patent/CY1112290T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5721549A (en) * | 1980-07-09 | 1982-02-04 | Japan Exlan Co Ltd | Water absorbable nonwoven fiber product |
| JPH0754208A (ja) * | 1993-08-13 | 1995-02-28 | Teijin Ltd | 芯鞘型複合バインダー繊維 |
| JPH11200209A (ja) * | 1997-12-26 | 1999-07-27 | Toyobo Co Ltd | 衛生材料用成形吸収体 |
| WO2005000372A1 (ja) * | 2003-06-26 | 2005-01-06 | Zuiko Corporation | 創傷被覆材および創傷被覆材キット |
| JP2006169173A (ja) * | 2004-12-16 | 2006-06-29 | Toyobo Co Ltd | シート状パック材の使用方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8350117B2 (en) | 2006-06-29 | 2013-01-08 | Biocell Gesellschaft Fuer Biotechnology Mbh | Wound cover |
| JP2016540593A (ja) * | 2013-12-20 | 2016-12-28 | エイチシーピー ヘルスケア アジア ピーティーイー.リミテッド | 空洞創傷を充填するための複合材料 |
| CN113682244A (zh) * | 2020-05-18 | 2021-11-23 | 日本宝翎株式会社 | 成型用基材 |
| JP2021181671A (ja) * | 2020-05-18 | 2021-11-25 | 日本バイリーン株式会社 | 成形用基材 |
| JP7742717B2 (ja) | 2020-05-18 | 2025-09-22 | 日本バイリーン株式会社 | 成形用基材 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2032179A2 (de) | 2009-03-11 |
| CY1112290T1 (el) | 2015-12-09 |
| JP4988838B2 (ja) | 2012-08-01 |
| US20090306611A1 (en) | 2009-12-10 |
| ES2374508T3 (es) | 2012-02-17 |
| WO2008000720A2 (de) | 2008-01-03 |
| EP2032179B1 (de) | 2011-10-05 |
| BRPI0713430A2 (pt) | 2012-03-13 |
| SI2032179T1 (sl) | 2012-01-31 |
| PL2032179T3 (pl) | 2012-04-30 |
| CA2654916A1 (en) | 2008-01-03 |
| WO2008000720A3 (de) | 2009-03-19 |
| DK2032179T3 (da) | 2012-01-16 |
| CA2654916C (en) | 2014-09-23 |
| ATE526998T1 (de) | 2011-10-15 |
| US8350117B2 (en) | 2013-01-08 |
| PT2032179E (pt) | 2012-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7438264B2 (ja) | 創傷被覆材 | |
| CN102264323B (zh) | 创伤敷料 | |
| US12214090B2 (en) | Kind of wound dressing for haemostasis | |
| CN102858292B (zh) | 压迫敷料 | |
| ES2430688T3 (es) | Dispositivo médico | |
| JP4988838B2 (ja) | 創傷被覆材 | |
| US20060211972A1 (en) | Wound dressing | |
| EP2809363A1 (de) | Wundpflegeartikel, aufweisend mindestens eine oberfläche mit abrasiven eigenschaften | |
| WO2016020704A1 (en) | Wound dressing | |
| DE102012100842A1 (de) | Wundpflegeartikel, aufweisend mindestens eine Oberfläche mit abrasiven Eigenschaften | |
| KR20070120610A (ko) | 은 코팅 및 그 제조 방법 | |
| CN101979745A (zh) | 机械牢固的吸收性无纺纤维垫 | |
| CN101500620A (zh) | 伤口敷料 | |
| RU2719444C2 (ru) | Система для обработки ран | |
| RU2197272C1 (ru) | Абсорбирующий медицинский материал и изделия на его основе | |
| Cockbill | Dressings in wound management | |
| JPH1053519A (ja) | ヨウ素含有高吸水性繊維 | |
| PL244469B1 (pl) | Sposób otrzymywania materiałów opatrunkowych do zastosowania w leczeniu ran zespołu stopy cukrzycowej | |
| PL243533B1 (pl) | Opatrunek wielofunkcyjny do zastosowania w leczeniu ran zespołu stopy cukrzycowej |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100423 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101227 Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120308 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120405 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120426 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4988838 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |